Literature DB >> 11145999

Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum.

S R Grady1, N M Meinerz, J Cao, A M Reynolds, M R Picciotto, J P Changeux, J M McIntosh, M J Marks, A C Collins.   

Abstract

Acetylcholine release stimulated by nicotinic agonists was measured as radioactivity released from perfused synaptosomes prepared from mouse interpeduncular nucleus (IPN) that had been loaded with [(3)H]choline. Agonist-stimulated release was dependent upon external calcium and over 90% of released radioactivity was acetylcholine. The release process was characterized by dose response curves for 13 agonists and inhibition curves for six antagonists. alpha-Conotoxin MII did not inhibit this release, while alpha-conotoxin AuIB inhibited 50% of agonist-stimulated release. Comparison of this process with [(3)H]dopamine release from mouse striatal synaptosomes indicated that different forms of nicotinic acetylcholine receptors (nAChRs) may mediate these processes. This was confirmed by assays using mice homozygous for the beta 2 subunit null mutation. The deletion of the beta 2 subunit had no effect on agonist-stimulated acetylcholine release, but abolished agonist-stimulated release of dopamine from striatal synaptosomes. Mice heterozygous for the beta 2 subunit null mutation showed decreased dopamine release evoked by L-nicotine with no apparent change in EC(50) value, as well as similar decreases in both transient and persistent phases of release with no changes in desensitization rates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11145999     DOI: 10.1046/j.1471-4159.2001.00019.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  47 in total

1.  Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.

Authors:  Sharon R Grady; Ryan M Drenan; Scott R Breining; Daniel Yohannes; Charles R Wageman; Nikolai B Fedorov; Sheri McKinney; Paul Whiteaker; Merouane Bencherif; Henry A Lester; Michael J Marks
Journal:  Neuropharmacology       Date:  2010-01-28       Impact factor: 5.250

2.  Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.

Authors:  Janice W Smith; Adrian Mogg; Elisiana Tafi; Eleanor Peacey; Ian A Pullar; Philip Szekeres; Mark Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2006-11-18       Impact factor: 4.530

3.  Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path.

Authors:  Raad Nashmi; Cheng Xiao; Purnima Deshpande; Sheri McKinney; Sharon R Grady; Paul Whiteaker; Qi Huang; Tristan McClure-Begley; Jon M Lindstrom; Cesar Labarca; Allan C Collins; Michael J Marks; Henry A Lester
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

4.  Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).

Authors:  Linda P Dwoskin; B Matthew Joyce; Guangrong Zheng; Nichole M Neugebauer; Vamshi K Manda; Paul Lockman; Roger L Papke; Michael T Bardo; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2007-07-21       Impact factor: 5.858

5.  Evaluation of structurally diverse neuronal nicotinic receptor ligands for selectivity at the alpha6( *) subtype.

Authors:  Scott R Breining; Merouane Bencherif; Sharon R Grady; Paul Whiteaker; Michael J Marks; Charles R Wageman; Henry A Lester; Daniel Yohannes
Journal:  Bioorg Med Chem Lett       Date:  2009-05-27       Impact factor: 2.823

6.  Localized low-level re-expression of high-affinity mesolimbic nicotinic acetylcholine receptors restores nicotine-induced locomotion but not place conditioning.

Authors:  Y S Mineur; D H Brunzell; S R Grady; J M Lindstrom; J M McIntosh; M J Marks; S L King; M R Picciotto
Journal:  Genes Brain Behav       Date:  2008-12-11       Impact factor: 3.449

7.  [¹²⁵I]AT-1012, a new high affinity radioligand for the α3β4 nicotinic acetylcholine receptors.

Authors:  Jinhua Wu; David C Perry; James E Bupp; Faming Jiang; Willma E Polgar; Lawrence Toll; Nurulain T Zaveri
Journal:  Neuropharmacology       Date:  2013-10-03       Impact factor: 5.250

Review 8.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

Review 9.  The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

Authors:  Sharon R Grady; Outi Salminen; Duncan C Laverty; Paul Whiteaker; J Michael McIntosh; Allan C Collins; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

Review 10.  Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors.

Authors:  Layla Azam; J Michael McIntosh
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.